EU-South Korea trade deal with pharma impact moves forward
This article was originally published in Scrip
The European Commission has welcomed a decision by the EU Foreign Affairs Council to authorise the signing of a free trade agreement (FTA) with South Korea, which stands to have a major impact across many industry sectors including pharmaceuticals.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.